Gene therapy and the liver
The liver is where many gene and RNA therapies do their work. That is not the same as treating a liver disease. Of the gene and RNA therapies licensed or recommended in the UK that act on the liver, this platform has found none whose licensed use is liver failure, cirrhosis or chronic liver disease.
One example, in NICE's own words. In primary hyperoxaluria type 1, a genetic mutation causes the liver to produce excess oxalate, which builds up in the kidneys and urinary tract. The fault is in the liver. The damage is in the kidney.
Where this came from
Section 3 Committee discussion, 'Primary hyperoxaluria type 1' · status: current, verified 2026-09-02
Open
In PH1, a genetic mutation causes the liver to produce excess oxalate which builds up in the kidneys and urinary tract.
The relationship runs the other way as well. A gene therapy licensed in the UK for an inherited bleeding disorder — not for a liver condition — cannot be given to someone with cirrhosis or advanced scarring of the liver. The state of a person's liver decides whether they can have it.
Where this came from
Section 4.3 Contraindications, second and third bullets · status: current, verified 2026-09-02
Open
- Active infections, either acute or uncontrolled chronic (see section 4.4). - Patients with known advanced hepatic fibrosis, or cirrhosis (see section 4.4).
Chapter 2 Information about etranacogene dezaparvovec, section 2.1 · status: current, verified 2026-09-02
Open
Etranacogene dezaparvovec (Hemgenix, CSL Behring) has a conditional marketing authorisation 'for the treatment of severe and moderately severe haemophilia B (congenital factor IX deficiency) in adult patients without a history of factor IX inhibitors'.
Related
- Cirrhosis — should be avoided in
- Alcohol-related liver disease — related through cirrhosis
- Ascites — related through cirrhosis
- Hepatocellular carcinoma — related through cirrhosis
- Hepatic encephalopathy — related through cirrhosis
- Steatotic liver disease — related through cirrhosis
What we have not established
Relationships involving AAV vectors that we have not evidenced are listed, never drawn — a line would read as a weak relationship, which is a different and false claim.
- AAV vectors → Hepatocyte — not established
Evidence search date: 2026-09-02
Content reviewed and approved
What we have not established here
Known gaps on this concept:
NO CATALOGUE OF LIVER-TARGETED THERAPIES, BY DECISION. Givosiran, patisiran, vutrisiran, eplontersen, inclisiran and lumasiran were all acquired and verified with their exact NICE wording, populations and conditions. None is published as an entry. An adversarial review found the misreading risk highest for acute HEPATIC porphyria, whose name alone a reader with cirrhosis will take as their own condition, and noted that NICE guidance records liver transplant as an option for some people with that disease — which makes the misreading reasonable rather than careless.
THE UNIVERSAL NEGATIVE IS NOT CLAIMED. This page says that of the therapies acting on the liver which this platform examined, none is licensed for liver disease. It does NOT say that no such therapy exists anywhere. No systematic search of that question was recorded, and the difference is stated rather than glossed.
Givosiran raises liver transaminases, and NICE records that elevated transaminases have led to people stopping treatment. That is the single most relevant fact about that drug for this audience and it was surfaced by adversarial review rather than by the sweep. It is not published because the drug is not published.
MHRA confirmed by freedom-of-information response that there is no authorised product called Roctavian in the UK. Verified and unpublished: a page saying which gene therapies are NOT authorised would invite exactly the pipeline reading this phase forbids.
No content on gene or RNA therapies under investigation for liver disease itself — fazirsiran for alpha-1 antitrypsin deficiency, bepirovirsen for chronic hepatitis B, OTC deficiency gene therapy. All are investigational, none is licensed, and naming them would be pipeline language.
NHS genomic medicine services and the National Genomic Test Directory are not covered. NHS genomics largely delivers diagnosis, and this platform will not blur diagnosis into treatment.
No plain-language explanation of how gene therapy works. The plain layer carries two facts and stops.
What has changed here
2026-09-02 — Concept created at plain, clinical, specialist and research resolutions.
Phase 18, the last audience layer. The acceptance criteria required this phase to test an inversion — not 'gene therapy may treat your liver' but 'your liver determines whether you can have gene therapy at all'. The Hemgenix licence evidences it exactly.